Combination immunotherapy for cancer

Fearon, D. (June 2016) Combination immunotherapy for cancer. J Exp Med, 213 (7). p. 1115. ISSN 1540-9538 (Electronic)0022-1007 (Linking)

[thumbnail of Paper]
PDF (Paper)
Fearon J Exp Med 2016.pdf - Published Version

Download (1MB) | Preview
DOI: 10.1084/jem.2137insight2


In this issue, Chapuis et al. describe the response of a single patient with metastatic melanoma to combination immunotherapy with anti-CTLA4 and adoptive T cell therapy (1). Although JEM usually discourages the submission of single case studies, the editors, like the authors, realized that this patient was unusual. He had previously been treated with anti-CTLA4 and adoptive T cell therapy administered as monotherapies, with only possible slowing of tumor growth with the former, and no response to the latter. The subsequent complete and durable clinical response to simultaneous treatment with these two modalities, therefore, allowed an argument to be made that their combination was responsible for the improved outcome.

Item Type: Paper
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Fearon lab
Depositing User: Matt Covey
Date: 27 June 2016
Date Deposited: 01 Jul 2016 17:03
Last Modified: 06 Nov 2017 20:17
PMCID: PMC4925029
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving